Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Joaquin Maximiliano Espinosa

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-PHARM General Operations
Phone303/724-7389

    Collapse Research 
    Collapse research activities and funding
    U24AG092191     (ESPINOSA, JOAQUIN M.)Sep 30, 2024 - Aug 31, 2029
    NIH
    The INCLUDE Project Down Syndrome Biorepository (DS-Biorepository)
    Role: Principal Investigator
    U01HD116469     (ESPINOSA, JOAQUIN M.)Sep 20, 2024 - May 31, 2029
    NIH
    Human Trisome Project - Latin America Network
    Role: Principal Investigator
    R01HD113720     (FIDLER, DEBORAH J)Sep 4, 2024 - Aug 31, 2029
    NIH
    Risk for Severe/Profound Intellectual Disability in Down Syndrome
    Role: Co-Principal Investigator
    R33HD109748     (ESPINOSA, JOAQUIN M.)Sep 1, 2024 - Aug 31, 2027
    NIH
    Mechanistic investigation of therapies for Down Syndrome Regression Disorder
    Role: Principal Investigator
    OT2HD117033     (ESPINOSA, JOAQUIN M.)Jun 15, 2024 - Jun 14, 2025
    NIH
    Down Syndrome Connect Registry
    Role: Principal Investigator
    R25HD114950     (ESPINOSA, JOAQUIN M.)Jun 1, 2024 - May 31, 2029
    NIH
    Data Science for Diverse Scholars in Down Syndrome Research (DS3)
    Role: Principal Investigator
    R01DC021819     (ESPINOSA, JOAQUIN M.)May 3, 2024 - Apr 30, 2029
    NIH
    Multidimensional investigation of auditory dysfunction in Down syndrome
    Role: Principal Investigator
    R24OD035579     (GALBRAITH, MATTHEW D)Sep 19, 2023 - Aug 31, 2027
    NIH
    Trisomy 21 Model Atlas
    Role: Co-Principal Investigator
    R01HD110542     (FIDLER, DEBORAH J)Sep 1, 2023 - Jun 30, 2028
    NIH
    Autism in Young Children with Down Syndrome
    Role: Co-Principal Investigator
    R61HD109748     (ESPINOSA, JOAQUIN M.)Sep 9, 2022 - Jun 30, 2024
    NIH
    Mechanistic investigation of therapies for Down Syndrome Regression Disorder
    Role: Principal Investigator
    U2CHL156291     (RESNICK, ADAM CAIN)Sep 26, 2020 - Aug 31, 2025
    NIH
    Data Management and Portal for the INCLUDE (DAPI) Project
    Role: Co-Principal Investigator
    R33AR077495     (ESPINOSA, JOAQUIN M.)Sep 25, 2019 - Jul 31, 2025
    NIH
    JAK Inhibition in Down Syndrome
    Role: Principal Investigator
    R61AR077495     (ESPINOSA, JOAQUIN M.)Sep 25, 2019 - Apr 30, 2022
    NIH
    JAK Inhibition in Down Syndrome
    Role: Principal Investigator
    R01AI150305     (ESPINOSA, JOAQUIN M.)Sep 18, 2019 - Mar 31, 2024
    NIH
    Understanding Down Syndrome as an Interferonopathy
    Role: Principal Investigator
    R01GM120109     (ESPINOSA, JOAQUIN M.)Sep 21, 2016 - Jul 31, 2020
    NIH
    Mechanisms of gene expression control during the cellular response to hypoxia
    Role: Principal Investigator
    R01CA117907     (ESPINOSA, JOAQUIN M.)May 26, 2006 - Jan 31, 2023
    NIH
    Mechanisms of gene expression control in the p53 network
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Cozzolino K, Sanford L, Hunter S, Molison K, Erickson B, Jones T, Courvan MCS, Ajit D, Galbraith MD, Espinosa JM, Bentley DL, Allen MA, Dowell RD, Taatjes DJ. Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome. bioRxiv. 2024 May 28. PMID: 37461585.
      View in: PubMed
    2. Wolin AR, Vincent MY, Hotz T, Purdy SC, Rosenbaum SR, Hughes CJ, Hsu JY, Oliphant MUJ, Armstrong B, Wessells V, Varella-Garcia M, Galbraith MD, Pierce A, Wang D, Venkataraman S, Danis E, Veo B, Serkova N, Espinosa JM, Gustafson DL, Vibhakar R, Ford HL. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. Neuro Oncol. 2023 12 08; 25(12):2287-2301. PMID: 37486991.
      View in: PubMed
    3. D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz JA, Zhang X, Bartsch KW, Galbraith MD, Espinosa JM, Gordeuk VR, Gladwin MT. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment. Haematologica. 2023 12 01; 108(12):3418-3432. PMID: 37439373.
      View in: PubMed
    4. Linder SJ, Bernasocchi T, Mart?nez-Pastor B, Sullivan KD, Galbraith MD, Lewis CA, Ferrer CM, Boon R, Silveira GG, Cho HM, Vidoudez C, Shroff S, Oliveira-Costa JP, Ross KN, Massri R, Matoba Y, Kim E, Rueda BR, Stott SL, Gottlieb E, Espinosa JM, Mostoslavsky R. Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cells. Nat Metab. 2023 Dec; 5(12):2131-2147. PMID: 37957387.
      View in: PubMed
    5. Fridman V, Sillau S, Ritchie A, Bockhorst J, Coughlan C, Araya P, Espinosa JM, Smith K, Lange EM, Lange LA, Ghormli LE, Drews KL, Zeitler P, Reusch JEB. Plasma neurofilament light chain concentrations are elevated in youth-onset type 2 diabetes and associated with neuropathy. J Peripher Nerv Syst. 2023 09; 28(3):460-470. PMID: 37341347.
      View in: PubMed
    6. Ludwig MP, Galbraith MD, Eduthan NP, Hill AA, Clay MR, Tellez CM, Wilky BA, Elias A, Espinosa JM, Sullivan KD. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway. Cancer Res. 2023 08 01; 83(15):2543-2556. PMID: 37205634.
      View in: PubMed
    7. Thomas SN, Niemeyer BF, Jimenez-Valdes RJ, Kaiser AJ, Espinosa JM, Sullivan KD, Goodspeed A, Costello JC, Alder JK, Ca?as-Arranz R, Garc?a-Sastre A, Benam KH. Down syndrome is associated with altered frequency and functioning of tracheal multiciliated cells, and response to influenza virus infection. iScience. 2023 Aug 18; 26(8):107361. PMID: 37554445.
      View in: PubMed
    8. Galbraith MD, Rachubinski AL, Smith KP, Araya P, Waugh KA, Enriquez-Estrada B, Worek K, Granrath RE, Kinning KT, Paul Eduthan N, Ludwig MP, Hsieh EWY, Sullivan KD, Espinosa JM. Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition. Sci Adv. 2023 06 28; 9(26):eadg6218. PMID: 37379383.
      View in: PubMed
    9. DeBoer EM, Wolter-Warmerdam K, Deterding RR, Marmolejo J, Blumenthal T, Espinosa JM, Hickey F, Wagner BD. Cardiopulmonary Phenotypes and Protein Signatures in Children With Down Syndrome. Clin Pediatr (Phila). 2024 May; 63(4):474-481. PMID: 37306037.
      View in: PubMed
    10. Chi C, Knight WE, Riching AS, Zhang Z, Tatavosian R, Zhuang Y, Moldovan R, Rachubinski AL, Gao D, Xu H, Espinosa JM, Song K. Interferon hyperactivity impairs cardiogenesis in Down syndrome via downregulation of canonical Wnt signaling. iScience. 2023 Jul 21; 26(7):107012. PMID: 37360690.
      View in: PubMed
    11. Waugh KA, Minter R, Baxter J, Chi C, Galbraith MD, Tuttle KD, Eduthan NP, Kinning KT, Andrysik Z, Araya P, Dougherty H, Dunn LN, Ludwig M, Schade KA, Tracy D, Smith KP, Granrath RE, Busquet N, Khanal S, Anderson RD, Cox LL, Estrada BE, Rachubinski AL, Lyford HR, Britton EC, Fantauzzo KA, Orlicky DJ, Matsuda JL, Song K, Cox TC, Sullivan KD, Espinosa JM. Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. Nat Genet. 2023 06; 55(6):1034-1047. PMID: 37277650.
      View in: PubMed
    12. D'Alessandro A, Nouraie SM, Zhang Y, Cendali F, Gamboni F, Reisz JA, Zhang X, Bartsch KW, Galbraith MD, Espinosa JM, Gordeuk VR, Gladwin MT. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients, as a function of therapeutic transfusion and hydroxyurea treatment. bioRxiv. 2023 Apr 06. PMID: 37066337.
      View in: PubMed
    13. Szwarc MM, Guarnieri AL, Joshi M, Duc HN, Laird MC, Pandey A, Khanal S, Dohm E, Bui AK, Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. FAM193A is a positive regulator of p53 activity. Cell Rep. 2023 03 28; 42(3):112230. PMID: 36897777.
      View in: PubMed
    14. Lesteberg KE, Araya P, Waugh KA, Chauhan L, Espinosa JM, Beckham JD. Severely ill and high-risk COVID-19 patients exhibit increased peripheral circulation of CD62L+ and perforin+ T cells. Front Immunol. 2023; 14:1113932. PMID: 36817450.
      View in: PubMed
    15. Tatavosian R, Donovan MG, Galbraith MD, Duc HN, Szwarc MM, Joshi MU, Frieman A, Bilousova G, Cao Y, Smith KP, Song K, Rachubinski AL, Andrysik Z, Espinosa JM. Cell differentiation modifies the p53 transcriptional program through a combination of gene silencing and constitutive transactivation. Cell Death Differ. 2023 04; 30(4):952-965. PMID: 36681780.
      View in: PubMed
    16. Donovan MG, Galbraith MD, Espinosa JM. Multi-omics investigation reveals functional specialization of transcriptional cyclin dependent kinases in cancer biology. Sci Rep. 2022 12 28; 12(1):22505. PMID: 36577800.
      View in: PubMed
    17. Araya P, Kinning KT, Coughlan C, Smith KP, Granrath RE, Enriquez-Estrada BA, Worek K, Sullivan KD, Rachubinski AL, Wolter-Warmerdam K, Hickey F, Galbraith MD, Potter H, Espinosa JM. IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome. Cell Rep. 2022 12 27; 41(13):111883. PMID: 36577365.
      View in: PubMed
    18. Andrysik Z, Sullivan KD, Kieft JS, Espinosa JM. PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response. Nat Commun. 2022 12 01; 13(1):7400. PMID: 36456590.
      View in: PubMed
    19. Freitas KA, Belk JA, Sotillo E, Quinn PJ, Ramello MC, Malipatlolla M, Daniel B, Sandor K, Klysz D, Bjelajac J, Xu P, Burdsall KA, Tieu V, Duong VT, Donovan MG, Weber EW, Chang HY, Majzner RG, Espinosa JM, Satpathy AT, Mackall CL. Enhanced T cell effector activity by targeting the Mediator kinase module. Science. 2022 Nov 11; 378(6620):eabn5647. PMID: 36356142.
      View in: PubMed
    20. McCurdy BL, Jewett CE, Stemm-Wolf AJ, Duc HN, Joshi M, Espinosa JM, Prekeris R, Pearson CG. Trisomy 21 increases microtubules and disrupts centriolar satellite localization. Mol Biol Cell. 2022 07 01; 33(8). PMID: 35476505.
      View in: PubMed
    21. Galbraith MD, Kinning KT, Sullivan KD, Araya P, Smith KP, Granrath RE, Shaw JR, Baxter R, Jordan KR, Russell S, Dzieciatkowska M, Reisz JA, Gamboni F, Cendali F, Ghosh T, Guo K, Wilson CC, Santiago ML, Monte AA, Bennett TD, Hansen KC, Hsieh EWY, D'Alessandro A, Espinosa JM. Specialized interferon action in COVID-19. Proc Natl Acad Sci U S A. 2022 03 15; 119(11). PMID: 35217532.
      View in: PubMed
    22. Klein JA, Li Z, Rampam S, Cardini J, Ayoub A, Shaw P, Rachubinski AL, Espinosa JM, Zeldich E, Haydar TF. Sonic Hedgehog Pathway Modulation Normalizes Expression of Olig2 in Rostrally Patterned NPCs With Trisomy 21. Front Cell Neurosci. 2021; 15:794675. PMID: 35058753.
      View in: PubMed
    23. Pham AT, Rachubinski AL, Enriquez-Estrada B, Worek K, Griffith M, Espinosa JM. JAK inhibition for treatment of psoriatic arthritis in Down syndrome. Rheumatology (Oxford). 2021 09 01; 60(9):e309-e311. PMID: 33630031.
      View in: PubMed
    24. Sullivan KD, Galbraith MD, Kinning KT, Bartsch KW, Levinsky NC, Araya P, Smith KP, Granrath RE, Shaw JR, Baxter RM, Jordan KR, Russell SA, Dzieciatkowska ME, Reisz JA, Gamboni F, Cendali FI, Ghosh T, Monte AA, Bennett TD, Miller MG, Hsieh EW, D'Alessandro A, Hansen KC, Espinosa JM. The COVIDome Explorer researcher portal. Cell Rep. 2021 08 17; 36(7):109527. PMID: 34348131.
      View in: PubMed
    25. Liggett LA, Galbraith MD, Smith KP, Sullivan KD, Granrath RE, Enriquez-Estrada B, Kinning KT, Shaw JR, Rachubinski AL, Espinosa JM, DeGregori J. Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation. Blood Adv. 2021 04 13; 5(7):1791-1796. PMID: 33787858.
      View in: PubMed
    26. Sullivan KD, Galbraith MD, Kinning KT, Bartsch K, Levinsky N, Araya P, Smith KP, Granrath RE, Shaw JR, Baxter R, Jordan KR, Russell S, Dzieciatkowska M, Reisz JA, Gamboni F, Cendali F, Ghosh T, Monte AA, Bennett TD, Miller MG, Hsieh EWY, D'Alessandro A, Hansen KC, Espinosa JM. The COVIDome Explorer Researcher Portal. medRxiv. 2021 Mar 08. PMID: 33758879.
      View in: PubMed
    27. Andrysik Z, Bender H, Galbraith MD, Espinosa JM. Multi-omics analysis reveals contextual tumor suppressive and oncogenic gene modules within the acute hypoxic response. Nat Commun. 2021 03 02; 12(1):1375. PMID: 33654095.
      View in: PubMed
    28. Galbraith MD, Kinning KT, Sullivan KD, Baxter R, Araya P, Jordan KR, Russell S, Smith KP, Granrath RE, Shaw J, Dzieciatkowska M, Ghosh T, Monte AA, D'Alessandro A, Hansen KC, Bennett TD, Hsieh EWY, Espinosa JM. Seroconversion stages COVID19 into distinct pathophysiological states. medRxiv. 2020 Dec 07. PMID: 33330890.
      View in: PubMed
    29. Vita S, Di Bari V, Corpolongo A, Goletti D, Espinosa J, Petracca S, Palmieri F, Nicastri E. Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome. Int J Infect Dis. 2021 Feb; 103:607-610. PMID: 33271290.
      View in: PubMed
    30. Tuttle KD, Waugh KA, Araya P, Minter R, Orlicky DJ, Ludwig M, Andrysik Z, Burchill MA, Tamburini BAJ, Sempeck C, Smith K, Granrath R, Tracy D, Baxter J, Espinosa JM, Sullivan KD. JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. Cell Rep. 2020 11 17; 33(7):108407. PMID: 33207208.
      View in: PubMed
    31. Deigendesch N, Hirsiger JR, Bigler MB, Ghosh A, Harder D, Jauch A, Espinosa JM, Recher M, Navarini A, Daikeler T, Berger CT. Tumoural soft tissue calcification in Down syndrome: association with heterozygous germline SAMD9 mutation and hyperactive type I interferon signaling. Rheumatology (Oxford). 2020 11 01; 59(11):e102-e104. PMID: 32594144.
      View in: PubMed
    32. Snyder HM, Bain LJ, Brickman AM, Carrillo MC, Esbensen AJ, Espinosa JM, Fernandez F, Fortea J, Hartley SL, Head E, Hendrix J, Kishnani PS, Lai F, Lao P, Lemere C, Mobley W, Mufson EJ, Potter H, Zaman SH, Granholm AC, Rosas HD, Strydom A, Whitten MS, Rafii MS. Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimers Dement. 2020 07; 16(7):1065-1077. PMID: 32544310.
      View in: PubMed
    33. Espinosa JM. Down Syndrome and COVID-19: A Perfect Storm? Cell Rep Med. 2020 05 19; 1(2):100019. PMID: 32501455.
      View in: PubMed
    34. Espinosa JM. Transcriptional control by enhancers: working remotely for improved performance. Transcription. 2020 02; 11(1):1-2. PMID: 32054432.
      View in: PubMed
    35. Waugh KA, Araya P, Pandey A, Jordan KR, Smith KP, Granrath RE, Khanal S, Butcher ET, Estrada BE, Rachubinski AL, McWilliams JA, Minter R, Dimasi T, Colvin KL, Baturin D, Pham AT, Galbraith MD, Bartsch KW, Yeager ME, Porter CC, Sullivan KD, Hsieh EW, Espinosa JM. Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. Cell Rep. 2019 11 12; 29(7):1893-1908.e4. PMID: 31722205.
      View in: PubMed
    36. Powers RK, Culp-Hill R, Ludwig MP, Smith KP, Waugh KA, Minter R, Tuttle KD, Lewis HC, Rachubinski AL, Granrath RE, Carmona-Iragui M, Wilkerson RB, Kahn DE, Joshi M, Lle? A, Blesa R, Fortea J, D'Alessandro A, Costello JC, Sullivan KD, Espinosa JM. Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. Nat Commun. 2019 10 18; 10(1):4766. PMID: 31628327.
      View in: PubMed
    37. Steinparzer I, Sedlyarov V, Rubin JD, Eislmayr K, Galbraith MD, Levandowski CB, Vcelkova T, Sneezum L, Wascher F, Amman F, Kleinova R, Bender H, Andrysik Z, Espinosa JM, Superti-Furga G, Dowell RD, Taatjes DJ, Kovarik P. Transcriptional Responses to IFN-? Require Mediator Kinase-Dependent Pause Release and Mechanistically Distinct CDK8 and CDK19 Functions. Mol Cell. 2019 11 07; 76(3):485-499.e8. PMID: 31495563.
      View in: PubMed
    38. Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Sawyer BT, Sullivan KD, Khanal S, Joshi M, Ferchaud-Roucher V, Smith H, Vanderlinden LA, Brubaker SW, Caino CM, Kim H, Espinosa JM, Richer JK, Bitler BG. Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination. iScience. 2019 Sep 27; 19:474-491. PMID: 31437751.
      View in: PubMed
    39. Rachubinski AL, Estrada BE, Norris D, Dunnick CA, Boldrick JC, Espinosa JM. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Rep. 2019 Apr; 5(4):365-367. PMID: 31008170.
      View in: PubMed
    40. Espinosa JM. Transcriptional CDKs in the spotlight. Transcription. 2019 04; 10(2):45-46. PMID: 30946639.
      View in: PubMed
    41. Oliphant MUJ, Vincent MY, Galbraith MD, Pandey A, Zaberezhnyy V, Rudra P, Johnson KR, Costello JC, Ghosh D, DeGregori J, Espinosa JM, Ford HL. SIX2 Mediates Late-Stage Metastasis via Direct Regulation of SOX2 and Induction of a Cancer Stem Cell Program. Cancer Res. 2019 02 15; 79(4):720-734. PMID: 30606720.
      View in: PubMed
    42. Abraham CG, Ludwig MP, Andrysik Z, Pandey A, Joshi M, Galbraith MD, Sullivan KD, Espinosa JM. ?Np63a Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep. 2018 09 18; 24(12):3224-3236. PMID: 30232004.
      View in: PubMed
    43. Fleenor CJ, Arends T, Lei H, ?hsberg J, Okuyama K, Kuruvilla J, Cristobal S, Rabe JL, Pandey A, Danhorn T, Straign D, Espinosa JM, Warming S, Pietras EM, Sigvardsson M, Hagman JR. Zinc Finger Protein 521 Regulates Early Hematopoiesis through Cell-Extrinsic Mechanisms in the Bone Marrow Microenvironment. Mol Cell Biol. 2018 09 01; 38(17). PMID: 29915154.
      View in: PubMed
    44. Galati DF, Sullivan KD, Pham AT, Espinosa JM, Pearson CG. Trisomy 21 Represses Cilia Formation and Function. Dev Cell. 2018 09 10; 46(5):641-650.e6. PMID: 30100262.
      View in: PubMed
    45. Guarnieri AL, Towers CG, Drasin DJ, Oliphant MUJ, Andrysik Z, Hotz TJ, Vartuli RL, Linklater ES, Pandey A, Khanal S, Espinosa JM, Ford HL. The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene. 2018 07; 37(28):3879-3893. PMID: 29662198.
      View in: PubMed
    46. Fitzwalter BE, Towers CG, Sullivan KD, Andrysik Z, Hoh M, Ludwig M, O'Prey J, Ryan KM, Espinosa JM, Morgan MJ, Thorburn A. Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. Dev Cell. 2018 03 12; 44(5):555-565.e3. PMID: 29533771.
      View in: PubMed
    47. Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 2018 01; 25(1):133-143. PMID: 29125602.
      View in: PubMed
    48. Sullivan KD, Evans D, Pandey A, Hraha TH, Smith KP, Markham N, Rachubinski AL, Wolter-Warmerdam K, Hickey F, Espinosa JM, Blumenthal T. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Sci Rep. 2017 11 01; 7(1):14818. PMID: 29093484.
      View in: PubMed
    49. Hamlett ED, Ledreux A, Potter H, Chial HJ, Patterson D, Espinosa JM, Bettcher BM, Granholm AC. Exosomal biomarkers in Down syndrome and Alzheimer's disease. Free Radic Biol Med. 2018 01; 114:110-121. PMID: 28882786.
      View in: PubMed
    50. Audetat KA, Galbraith MD, Odell AT, Lee T, Pandey A, Espinosa JM, Dowell RD, Taatjes DJ. A Kinase-Independent Role for Cyclin-Dependent Kinase 19 in p53 Response. Mol Cell Biol. 2017 07 01; 37(13). PMID: 28416637.
      View in: PubMed
    51. Liang K, Volk AG, Haug JS, Marshall SA, Woodfin AR, Bartom ET, Gilmore JM, Florens L, Washburn MP, Sullivan KD, Espinosa JM, Cannova J, Zhang J, Smith ER, Crispino JD, Shilatifard A. Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. Cell. 2017 Jan 12; 168(1-2):59-72.e13. PMID: 28065413.
      View in: PubMed
    52. Andrews FH, Tong Q, Sullivan KD, Cornett EM, Zhang Y, Ali M, Ahn J, Pandey A, Guo AH, Strahl BD, Costello JC, Espinosa JM, Rothbart SB, Kutateladze TG. Multivalent Chromatin Engagement and Inter-domain Crosstalk Regulate MORC3 ATPase. Cell Rep. 2016 09 20; 16(12):3195-3207. PMID: 27653685.
      View in: PubMed
    53. Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MUJ, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nat Commun. 2015 Dec 21; 6:10077. PMID: 26687066.
      View in: PubMed
    54. Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 May; 14(5):1117-29. PMID: 25758253.
      View in: PubMed
    55. Warren CJ, Van Doorslaer K, Pandey A, Espinosa JM, Pyeon D. Role of the host restriction factor APOBEC3 on papillomavirus evolution. Virus Evol. 2015 Jan; 1(1). PMID: 27570633.
      View in: PubMed
    56. Allen MA, Andrysik Z, Dengler VL, Mellert HS, Guarnieri A, Freeman JA, Sullivan KD, Galbraith MD, Luo X, Kraus WL, Dowell RD, Espinosa JM. Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. Elife. 2014 May 27; 3:e02200. PMID: 24867637.
      View in: PubMed
    57. Galbraith MD, Saxton J, Li L, Shelton SJ, Zhang H, Espinosa JM, Shaw PE. ERK phosphorylation of MED14 in promoter complexes during mitogen-induced gene activation by Elk-1. Nucleic Acids Res. 2013 Dec; 41(22):10241-53. PMID: 24049075.
      View in: PubMed
    58. Freeman JA, Espinosa JM. The impact of post-transcriptional regulation in the p53 network. Brief Funct Genomics. 2013 Jan; 12(1):46-57. PMID: 23242178.
      View in: PubMed
    59. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 2010 Jan 22; 140(2):280-93. PMID: 20141841.
      View in: PubMed
    60. Beckerman R, Donner AJ, Mattia M, Peart MJ, Manley JL, Espinosa JM, Prives C. A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. Genes Dev. 2009 Jun 01; 23(11):1364-77. PMID: 19487575.
      View in: PubMed
    61. Knuesel MT, Meyer KD, Donner AJ, Espinosa JM, Taatjes DJ. The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Mol Cell Biol. 2009 Feb; 29(3):650-61. PMID: 19047373.
      View in: PubMed
    62. Espinosa JM. Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene. 2008 Jul 03; 27(29):4013-23. PMID: 18278067.
      View in: PubMed
    63. Glover-Cutter K, Kim S, Espinosa J, Bentley DL. RNA polymerase II pauses and associates with pre-mRNA processing factors at both ends of genes. Nat Struct Mol Biol. 2008 Jan; 15(1):71-8. PMID: 18157150.
      View in: PubMed
    64. Kalet BT, McBryde MB, Espinosa JM, Koch TH. Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism. J Med Chem. 2007 Sep 06; 50(18):4493-500. PMID: 17696516.
      View in: PubMed
    65. Donner AJ, Szostek S, Hoover JM, Espinosa JM. CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell. 2007 Jul 06; 27(1):121-33. PMID: 17612495.
      View in: PubMed
    66. Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev. 2006 Mar 01; 20(5):601-12. PMID: 16510875.
      View in: PubMed
    Espinosa's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (304) concept(s)
    _
    Co-Authors Expand Description
    See all (78) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)